Objective To observe the clinical effect and safety of sitagliptin phosphate combined with insulin aspart 30 in the treatment of type 2 diabetes mellitus. Methods There were 60 patients in our hospital’s outpatient department, who receiving insulin aspart 30 for treatment without reaching standard level of blood glucose. They were randomly divided into sitagliptin group and metformin group, and each group contained 30 cases. The sitagliptin group received oral administration of sitagliptin for 100 mg/d, and the metformin group was given metformin for 1.0 g/d. Adjustment of insulin was made according to their blood glucose monitoring conditions. The treatment lasted for 12 weeks. Fasting plasma glucose (FPG), 2 h postprandial blood glucose (2hPG), and glycosylated hemoglobin (HbA1c) were detected in the two groups before and after treatment. Adverse reactions were observed. Results There were 29 completed cases in the sitagliptin group, and 28 completed cases in the metformin group. Both groups had obviously lower levels of fasting blood glucose, 2 h postprandial blood glucose, and glycosylated hemoglobin after treatment than those before treatment. The difference had statistical significance (P<0.05). After treatment, the sitagliptin group was better than the metformin group (P<0.05). No severe adverse reactions were found in the two groups. Conclusion Sitagliptin phosphate combined with insulin aspart 30 has precise effect in the treatment of type 2 diabetes mellitus. It can control blood glucose effectively with good tolerance and no obviously adverse reactions.%目的：观察磷酸西格列汀联合门冬胰岛素30治疗2型糖尿病的临床疗效与安全性。方法接受门冬胰岛素30治疗的血糖控制不理想的2型糖尿病患者60例,随机分为西格列汀组和二甲双胍组,各30例。西格列汀组给予西格列汀100 mg/d口服,二甲双胍组给予二甲双胍1.0 g/d,两组根据血糖监测情况适时调整门冬胰岛素30用量,疗程12周。检测两组用药前后空腹血糖(FPG),餐后2 h血糖(2 h PG),糖化血红蛋白(HbA1c),观察不良反应。结果西格列汀组完成29例,二甲双胍组完成28例。两组患者的空腹血糖、餐后2 h血糖及糖化血红蛋白值均较治疗前明显下降,差异有统计学意义(P<0.05)；治疗后两组比较,西格列汀组优于二甲双胍组(P<0.05)。均无严重不良反应。结论磷酸西格列汀联合门冬胰岛素30治疗2型糖尿病有明显疗效,可以更好控制血糖,无明显不良反应,耐受性好。
展开▼
